Record overview
Status and phase
Status: TERMINATED
Phase: PHASE1, PHASE2
Sponsor: Transgene
Condition: Hepatocellular Carcinoma (HCC)
NCT03071094
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).